National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program

Diagn Microbiol Infect Dis. 1998 May;31(1):327-32. doi: 10.1016/s0732-8893(97)00240-x.


Surveillance of nosocomial blood stream infections (BSI) in the USA between April 1995 and June 1996 revealed that Candida was the fourth leading cause of nosocomial BSI, accounting for 8% of all infections. Fifty-two percent of 379 episodes of candidemia were due to Candida albicans. In vitro susceptibility studies using the 1997 National Committee for Clinical Laboratory Standards reference method demonstrated that 92% of C. albicans isolates were susceptible to 5-fluorocytosine and 90% were susceptible to fluconazole and itraconazole. Geographic variation in susceptibility of fluconazole and itraconazole was observed. Isolates from the Northwest and Southeast regions were more frequently resistant to fluconazole (13.3-15.5%) and to itraconazole (17.2-20.0%) than those from the Northeast and Southwest regions (2.9-5.5% resistant to fluconazole and itraconazole). Continued surveillance for infections caused by C. albicans and other species of Candida among hospitalized patients is recommended.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology*
  • Candida albicans / drug effects*
  • Candida albicans / isolation & purification
  • Candidiasis / drug therapy
  • Candidiasis / microbiology*
  • Cross Infection / drug therapy
  • Cross Infection / microbiology*
  • Drug Resistance, Microbial
  • Fluconazole / pharmacology
  • Fungemia / drug therapy
  • Fungemia / microbiology*
  • Humans
  • Itraconazole / pharmacology
  • Microbial Sensitivity Tests


  • Antifungal Agents
  • Itraconazole
  • Fluconazole